Answers are grounded in this paper and cite their sources.
Amyloid-related imaging abnormalities (ARIA) are potentially serious adverse side effects of amyloid-targeting treatment (ATT) for Alzheimer’s disease. Pre-screening patients to identify high-risk cohorts based on biological and imaging biomarkers could enable more personalized treatment plans and reduce unnecessary risk and costs. Risk factors are well-characterized from trials, and anti-amyloid therapy is increasingly recommended. There is hence a growing need for pretreatment risk stratification tools. Clinically useful tools require individualized predictive models, but existing risk modeling is limited to pharmacokinetic analyses and frameworks using a small handful of pre-specified factors. None integrate multimodal pre-treatment data, use foundation models, or show validation in real-world cohorts. We propose a framework combining multimodal foundation model architectures (imaging, tabular, vision-language) with ARIA-specific design choices, including prediction heads separating ARIA-E and ARIA-H, severity grading, time-to-event modeling, and APOE -stratified monitoring decisions, validated through real-world hospital data in patients receiving ATT.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: